John W. Hayslip

526 total citations
11 papers, 222 citations indexed

About

John W. Hayslip is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, John W. Hayslip has authored 11 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in John W. Hayslip's work include Radiopharmaceutical Chemistry and Applications (2 papers), Acute Myeloid Leukemia Research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). John W. Hayslip is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (2 papers), Acute Myeloid Leukemia Research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). John W. Hayslip collaborates with scholars based in United States, Australia and Germany. John W. Hayslip's co-authors include Jamie L. Studts, Mary C. Politi, Kit N. Simpson, Jing‐Zhou Hou, Andrew H. Wei, Walter Fiedler, Wyndham H. Wilson, Richard F. Little, Ariela Noy and Seth M. Steinberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

John W. Hayslip

11 papers receiving 217 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John W. Hayslip United States 6 80 74 70 69 41 11 222
P. Talley United Kingdom 5 85 1.1× 112 1.5× 97 1.4× 17 0.2× 73 1.8× 6 296
Anastassia Negrouk Belgium 8 74 0.9× 54 0.7× 68 1.0× 16 0.2× 33 0.8× 23 212
Dorte Tholstrup Denmark 6 180 2.3× 55 0.7× 63 0.9× 12 0.2× 26 0.6× 10 303
Nicole Wong Doo Australia 10 124 1.6× 65 0.9× 28 0.4× 13 0.2× 43 1.0× 29 317
Hans‐Jürgen Hurtz Germany 4 109 1.4× 24 0.3× 94 1.3× 10 0.1× 104 2.5× 5 272
Leo W.K. Cheung United States 8 114 1.4× 80 1.1× 161 2.3× 26 0.4× 123 3.0× 14 333
Gordon McVie Italy 9 189 2.4× 53 0.7× 36 0.5× 39 0.6× 53 1.3× 21 330
Vanessa Tyrrell Australia 8 42 0.5× 27 0.4× 12 0.2× 38 0.6× 53 1.3× 16 230
Nupur Mittal United States 9 31 0.4× 45 0.6× 20 0.3× 11 0.2× 28 0.7× 37 217
Nektaria Alexandri Germany 8 50 0.6× 24 0.3× 135 1.9× 16 0.2× 9 0.2× 23 155

Countries citing papers authored by John W. Hayslip

Since Specialization
Citations

This map shows the geographic impact of John W. Hayslip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Hayslip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Hayslip more than expected).

Fields of papers citing papers by John W. Hayslip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Hayslip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Hayslip. The network helps show where John W. Hayslip may publish in the future.

Co-authorship network of co-authors of John W. Hayslip

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Hayslip. A scholar is included among the top collaborators of John W. Hayslip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Hayslip. John W. Hayslip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Lim, Kian‐Huat, Rachael A. Safyan, Kimberly Perez, et al.. (2025). Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
2.
Falchook, Gerald S., Patricia LoRusso, Jonathan W. Goldman, et al.. (2024). Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2529–2529. 4 indexed citations
3.
Zhou, Qing, Lin Wu, Bo Jiang, et al.. (2023). Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.. Journal of Clinical Oncology. 41(16_suppl). 2570–2570. 4 indexed citations
4.
Wei, Andrew H., Pau Montesinos, Vladimir Ivanov, et al.. (2020). A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.. Journal of Clinical Oncology. 38(15_suppl). 7511–7511. 8 indexed citations
5.
Lin, Tara L., Stephen A. Strickland, Walter Fiedler, et al.. (2016). Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology. 34(15_suppl). 7007–7007. 30 indexed citations
6.
Dunleavy, Kieron, Michelle A. Fanale, Ann S. LaCasce, et al.. (2014). Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. Blood. 124(21). 395–395. 40 indexed citations
7.
Wiggins, Amanda T., et al.. (2013). Differences in Vitamin D Nutritional Status Between Newly Diagnosed Cancer Patients from Rural or Urban Settings in Kentucky. Nutrition and Cancer. 65(5). 653–658. 4 indexed citations
8.
Hayslip, John W., et al.. (2012). Decision Making and Distress Among Individuals Diagnosed with Follicular Lymphoma. Journal of Psychosocial Oncology. 30(4). 426–445. 13 indexed citations
9.
Hayslip, John W., et al.. (2012). Immunonutrition: Does It Have a Role in Improving Recovery in Patients Receiving a Stem Cell Transplant?. Nutrition and Cancer. 64(4). 503–507. 5 indexed citations
10.
Politi, Mary C., Jamie L. Studts, & John W. Hayslip. (2012). Shared Decision Making in Oncology Practice: What Do Oncologists Need to Know?. The Oncologist. 17(1). 91–100. 91 indexed citations
11.
Hayslip, John W. & Kit N. Simpson. (2008). Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65–70 Years with Follicular Lymphoma in Second Remission. Clinical Lymphoma & Myeloma. 8(3). 166–170. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Talley Breakdown of academic impact, for papers by Anastassia Negrouk Breakdown of academic impact, for papers by Dorte Tholstrup Breakdown of academic impact, for papers by Nicole Wong Doo Breakdown of academic impact, for papers by Hans‐Jürgen Hurtz Breakdown of academic impact, for papers by Leo W.K. Cheung Breakdown of academic impact, for papers by Gordon McVie Breakdown of academic impact, for papers by Vanessa Tyrrell Breakdown of academic impact, for papers by Nupur Mittal Breakdown of academic impact, for papers by Nektaria Alexandri
Rankless by CCL
2026